Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238539 | 1.00 | NR1H2 (0.56) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL30639835 | 1.00 | NR1H2 (0.56) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL21670176 | 1.00 | NR1H2 (0.56) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL30639814 | 1.00 | NR1H2 (0.56) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL31081870 | 1.00 | NR1H2 (0.56) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL21670174 | 1.00 | NR1H2 (0.56) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL23931069 | 0.89 | NR1H2 (0.50) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL1014216 | 0.88 | NR1H2 (0.65) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL30721755 | 0.88 | NR1H2 (0.65) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL2930155 | 0.88 | NR1H2 (0.65) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | disclosed |
| US-12065430-B2 | Indazole compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | ANTIOS THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | Antios Therapeutics, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2022-04-14 | — | — | US | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20200102314-A1 | SUBSTITUTED PYRROLIDINE COMPOUNDS | Epizyme, Inc. (US) | 2020-04-02 | — | — | US | disclosed |
| EP-3608326-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-02-12 | — | — | EP | disclosed |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | Epizyme, Inc. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | Epizyme, Inc. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | Epizyme, Inc. (US) | 2017-09-07 | — | — | US | disclosed |
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065430-B2 | Indazole compound or salt thereof | RCOR3, H1-3, BICRA | NR1H2 1338/4885PDE4B 3125/4885USP2 3856/4885 |
| US-20200102314-A1 | SUBSTITUTED PYRROLIDINE COMPOUNDS | SMYD2, SMYD3, SNRPD2 | NR1H2 3364/4885PDE4B 1559/4885USP2 903/4885 |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | HAVCR2, NR1H4, HCCS | NR1H2 9/4885PDE4B 1246/4885USP2 2537/4885 |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, NR1H4, HCCS | NR1H2 9/4885PDE4B 1246/4885USP2 2537/4885 |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | SMYD2, SMYD3, SNRPD2 | NR1H2 3364/4885PDE4B 1559/4885USP2 903/4885 |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, HDGF, SLC10A1 | NR1H2 17/4885PDE4B 1026/4885USP2 2428/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | NR1H2 2517/4885PDE4B 3995/4885USP2 1965/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | NR1H2 2872/4885PDE4B 2660/4885USP2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.